Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Advertisement
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

Pfizer Skeptical About Value-Based Contracting In Current Environment

'We have about 18 different projects underway but we've achieved' only one value-based deal, Pfizer CEO Ian Read says. 'The risks and incentives have to be with the providers. … That's how you get the best health care.'

Pricing Strategies Market Access

Drug Payment Experiments Coming To Medicare, Medicaid

Centers For Medicare and Medicaid Services releases 'request for information' on how to approach development of new payment models for prescription drugs in government-sponsored insurance.

Government Payers Reimbursement

Pharmacy Discount Rx Programs Can Enroll Medicare Members

HHS Office of Inspector General says it would not impose anti-kickback penalties against a pharmacy chain's plan to expand its membership benefits program, which includes discounts on prescription drugs, to enrollees in federal health care programs.

Compliance Medicare

Could Medicare 340B Payment Cuts Lead Hospitals To Buy At List Price?

Pew Charitable Trusts' Allan Coukell warns the Centers for Medicare and Medicaid Services that its proposal to reduce Medicare Part B drug payments to 340B hospitals may have 'unintended consequences.'

Pricing Strategies Medicare

Medicare Coding Change For Biosimilars Could Save $65bn, Firms Say

Biopharma manufacturers, payers and other stakeholders strongly support changing an Obama-era policy for reimbursing biosimilars under Medicare Part B in comments to the Centers for Medicare and Medicaid Services.

Biosimilars Medicare

Novartis Set 'Responsible' Price For Kymriah, Express Scripts Says

Drug pricing critic Steve Miller, chief medical officer with Express Scripts, praises Novartis' gene therapy pricing and promotes benefits of amortized payments tied to outcomes.

Pricing Debate Reimbursement
See All
Advertisement
UsernamePublicRestriction

Register